Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Title: 

NEOADJUVANT HORMONE THERAPY BEFORE RADICAL PROSTATECTOMY FOR CLINICAL STAGE C (T3, T4, NO, MO): 5–YEAR FOLLOW-UP

Type: PAPER
Author(s): JABALAMELI P.*,AYATI M.,NOROOZI M.R.,JAMSHIDIAN ETAL H.
 
 *
 
Name of Seminar: CONGREH ANJOMAN UROLOGY IRAN
Type of Seminar:  CONGRESS
Sponsor:  ANJOMAN OROLOGY
Date:  2005Volume 8
 
 
Abstract: 

PURPOSE: NEOADJUVANT HORMONE THERAPY BEFORE DEFINITIVE TREATMENT FOR LOCALLY ADVANCED PROSTATE CANCER AND CLINICAL RESPONSE FOLLOWING ANDROGEN ABLATION THERAPY.
MATERIALS & METHODS: A TOTAL OF 22 PATIENTS TREATED ANDROGEN ABLATION THERAPY FOR 16 WEEKS AND TREATED FURTHER WITH RADICAL PROSTATECTOMY.
THE TUMOR STAGES WERE T3 AND T4 AND THE TUMOR BURDEN WAS LARGER THAN 4 CM.
THE PATIENTS TREATED BY FLUTAMIDE AND DECPEPTYL FOR NEOADJUVANT ANDROGEN ABLATION.
RESULTS: CLINICAL STAGES WERE T (97%) AND T (3%) BEFORE HORMONE ABLATION THERAPY.
MEANS YEAR CANCER FREE SURVIVAL RATE WAS 75%. MOST OF THE PATIENTS WERE NOT A GOOD CANDIDATE FOR SURGICAL TREATMENT AND THEY WERE CANDIDATED FOR RADIOTHERAPY.
CONCLUSIONS: NEOADJUVANT HORMONE THERAPY IS A SUITABLE AND ACCEPTABLE TREATMENT MODALITY FOR STAGES T AND T OF PROSTATE CANCER.
A FREE PROGRESSION AND 5 YEARS SURVIVAL RATES OF 50% TO 90% IN COMPARISON OF RADIOTHERAPY IS ACCEPTED.

 
Keyword(s): 
 
 
Yearly Visit 35   tarjomyar
 
Latest on Blog
Enter SID Blog